Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
losartan (DuPont)
- Development stage
- Unknown
- Lead developer
- University of Utah
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Losartan** is an orally administered small-molecule angiotensin II receptor blocker that selectively antagonizes the angiotensin II type 1 receptor. It was originally developed for cardiovascular and renal indications and is marketed as losartan potassium tablets. In the University of Utah-sponsored SHAPER study, losartan is being repurposed as a stromal and perfusion-modulating adjunct after induction chemotherapy for borderline resectable or locally advanced unresectable pancreatic ductal adenocarcinoma; the study evaluates its use with hypofractionated radiation therapy, not as a fixed-dose combination product. By blocking angiotensin II signaling, losartan may reduce tumor-associated fibrosis and improve tumor blood flow and oxygenation, potentially supporting radiation delivery and response.
- Brand names
- ArbliCozaarCosaar
- Other names
- losartanlosartan potassium
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on losartan (DuPont).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on losartan (DuPont).